Indegene — Q4 FY25 earnings call

Call held 29 Apr 2025

Management summary

Indegene delivered a steady FY25 with nearly 10% revenue growth, driven primarily by mid-sized pharma clients outside the Top 20. While the company faces headwinds from two of its top five customers and macro-induced slowdowns in large transformational deals, it is aggressively pivoting toward GenAI with its new 'Cortex' platform. The acquisition of MJL Communications in the UK further strengthens its creative and medical writing capabilities following the successful integration of Trilogy.

Highlights

  • FY25 Revenue reached ₹28,393 million, representing a 9.6% YoY growth.

  • Q4 FY25 Revenue stood at ₹7,556 million, up 12.3% YoY and 4.9% QoQ.

  • Full-year PAT grew significantly by 20.8% YoY to ₹4,067 million.

  • EBITDA for FY25 was ₹5,622 million with a margin of 19.8%, a 90 bps contraction YoY.

  • USD 1 million+ clients increased to 41, up from 35 in the previous year.

  • Board approved a 100% dividend (approx ₹48 crores), representing 12% of PAT.

  • Management flagged a $1 million per quarter revenue impact starting Q1 FY26 due to a reconfiguration in the largest client's contract.

Concerns

  • Client Concentration and Revenue Leakage

Key financials

  1. Revenue 28,393 Mn +9.6%YoY
  2. EBITDA Margin 19.8%
  3. PAT 4,067 Mn +20.8%YoY
  4. Cash and Cash Equivalents ₹1,664 Cr
  5. Active Clients 73 +15.8%YoY

What they filed

Q1 FY27: revenue up 33.2%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue282 287 267 256 307 +9%290 +1%368 +38%341 +33%
EBITDA46 52 40 37 71 +54%38 −27%103 +158%60 +62%
Net profit45 50 54 45 60 +33%35 −30%72 +33%60 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Enterprise Commercial
    2% Growth2% Revenue Contribution (Top 20)
  • Omni-channel Activation
    13.2% Q4 Margin8% Q3 Margin
  • Enterprise Medical
    — Growth Status

Guidance & targets

Margin

  • EBITDA Margin Outlook Margin · FY26 · Medium confidence Fairly stable
    I would say that the margin outlook would be fairly stable even in the coming periods.

    — Suhas Prabhu, CFO

Capex

  • Capital Expenditure as % of Revenue Capex · FY26 · High confidence 1-odd percent
    So it's typically in that 1-odd percent of our revenues, the capital expenditure.

    — Suhas Prabhu, CFO

Other

  • R&D / Technology Spend as % of Revenue Other · FY26 · High confidence 2%
    consistently over the past 4, 5 years that has been in the vicinity of 2% of our revenue.

    — Suhas Prabhu, CFO

Dividend

  • Dividend Payout Dividend · FY25 · High confidence 100%
    I'm happy to share that the Board has approved a 100% dividend, subject to members' consent in the AGM.

    — Manish Gupta, Chairman and CEO

Risks & concerns

  • Client Concentration and Revenue Leakage

    high

    Headwinds in 2 of top 5 customers; largest customer renewal reconfiguration will cause a $1M/quarter revenue hit starting Q1 FY26.

    Management acknowledged

  • FDA Regulatory Delays

    medium

    20% reduction in FDA workforce could lead to slower submission reviews and disruptions in early engagement for biotech firms.

    Management acknowledged

  • Macro Uncertainty and Decision Slowdown

    medium

    U.S. tariffs and macro uncertainty are causing a slowdown in decision-making for large transformational initiatives.

    Management acknowledged

  • Currency Depreciation

    low

    Management maintains a 75-80% hedge on a 12-month forward basis to mitigate USD depreciation.

    Analyst downplayed

Areas of evasion (2)

  • Specific revenue guidance for FY26
  • Specific revenue potential of the MJL acquisition

Q&A highlights

2 direct
Slowdown in Enterprise Commercial Segment Direct
The growth has come down last year, and that is primarily due to the impact of these 2 customers... one of these customers has stabilized and will start growing... The other one might take a little bit more hit.

Explains why the core high-growth segment slowed to low single digits and identifies specific client-level leakage.

Asked by Shiwani, Monarch Networth Capital

Decline in Top 10 Accounts Direct
These two customers, what we lost in revenue, right, had impacted our overall growth by somewhere in that region of 6%.

Quantifies the massive 6% drag on total company growth caused by just two major accounts.

Asked by Ajay, Blue Argon Capital

Impact of FDA Staff Cuts Partial
On March 27, HHS announced a reduction of nearly 3,500 full-time FDA employees... this has led to a removal of top scientists... suggest potential delays in submission reviews.

Highlights a major external regulatory risk that could delay client product launches and Indegene's associated revenue.

Asked by Prakash Kapadia, Spark PMS

2 min read 5 chapters

Detailed narrative

Client Concentration Headwinds

Indegene faced significant challenges with its top-tier accounts in FY25. Two of its top five customers experienced headwinds, with one seeing volume reductions and the other undergoing a contract reconfiguration. This reconfiguration, involving a shift in the on-site/offshore mix for the largest customer, is expected to result in a $1 million revenue impact per quarter starting in Q1 FY26. Collectively, the revenue loss from these two accounts dragged down overall company growth by approximately 6%.

FDA Regulatory Environment Shift

A major external risk emerged with the announcement of a 20% reduction in the FDA workforce, totaling nearly 3,500 employees. Management noted that this reduction includes top scientists across key divisions like drugs and devices. While this creates uncertainty and potential delays in submission reviews for clients, Indegene views it as a medium-term opportunity to provide AI-driven solutions to bridge the bandwidth gaps created at the regulatory level.

GenAI and the Cortex Platform

The company is heavily betting on its new GenAI platform, Cortex, to drive future growth. Cortex codifies 26 years of operational experience to train AI models specifically for the life sciences industry, focusing on 'agentic workflows' and governance. While management admits it is still early for major closures, they are seeing positive reactions from clients and are embedding these AI capabilities into existing engagements to improve internal margins.

Strategic M&A and Integration

Indegene continues its strategy of 'tuck-in' acquisitions to broaden capabilities. The integration of Trilogy has already yielded multi-year wins with over $2 million in Annual Contract Value (ACV). The most recent acquisition of MJL Communications in the UK (for up to GBP 3.4 million) is intended to bolster creative and medical writing capabilities in Europe, allowing the company to compete for larger, global enterprise deals.

Margin and Cost Dynamics

FY25 EBITDA margins contracted by 90 bps to 19.8%, primarily due to a higher on-site employee mix and increased technology expenses. Q4 margins were further pressured by seasonal trends in vacation accruals and US payroll taxes. However, management expects margins to remain 'fairly stable' in FY26 as they gain operating leverage and benefit from a higher margin profile in the Omni-channel Activation segment, which saw margins jump to 13.2% in Q4.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls